Published in:
01-09-2003 | Original Paper
Pseudo-Bartter syndrome in a neonate on prostaglandin infusion
Authors:
Sofie Vanhaesebrouck, Karel Allegaert, Christine Vanhole, Hugo Devlieger, Marc Gewillig, Willem Proesmans
Published in:
European Journal of Pediatrics
|
Issue 9/2003
Login to get access
Abstract
We describe a case of iatrogenic pseudo-Bartter syndrome caused by administration of prostaglandin E1 (PGE1 alprostadil). Although the use of i.v. PGE1 is a well-established pharmacological therapy in neonates with a ductus-dependent congenital cardiopathy to ensure ductus-dependent flow, we could only find one other report on pseudo-Bartter syndrome related to PGE1 infusion. Conclusion: primary Bartter syndrome is associated with endogenous increased levels of prostaglandins. Therefore, we postulate that the dose of prostaglandin E1 administered, immaturity and the genetic background are all relevant factors involved in the phenotypic presentation of iatrogenic pseudo-Bartter syndrome in this preterm infant.